The efficacy and safety of weekly somatrogon treatment in turkish children with growth hormone deficiency: a real-world cohort study
Tahsin Gider, Edip Unal, Servet Yel, Barış Kolbaşı, Hüseyin Düzgün · 2026
Read The efficacy and safety of weekly somatrogon treatment in turkish children with growth hormone deficiency: a real-world cohort study by Tahsin Gider, Edip Unal, Servet Yel, Barış Kolbaşı, Hüseyin Düzgün (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13194275.txt.
Description
Tahsin Gider is first author on a 2026 real-world cohort study of weekly somatrogon treatment in Turkish children with growth hormone deficiency. Long-acting growth hormone cuts injection frequency from daily to weekly, which may help families stick with treatment. The study followed children aged three to eighteen treated for at least six months in routine practice.
Thirty-nine patients were included, treated for about eleven months on average. Yearly height gain averaged about ten centimeters, and a growth-related hormone marker rose into the normal range for most. In five children the marker ran too high, prompting dose cuts. No serious side effects occurred. Weekly treatment, the authors conclude, worked and was well tolerated, pending longer study.
Catalog record
| CREATOR | Tahsin Gider, Edip Unal, Servet Yel, Barış Kolbaşı, Hüseyin Düzgün |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |